PD-1 was first cloned in 1992 [146] and later shown to be a negative regulator of the immune system [147], and in 2002, an antibody against PD-L1, a ligand of PD-1, showed therapeutic effect on cancers in a mouse model [148]. This evidence concerns the gene CD274 and cancer.